Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax with idarubicin and cytarabine for frontline acute myeloid leukemia in older adults
ACTRN12616000445471Phase 2Recruiting
- Sponsor
- Alfred Health
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by Alfred Health. Primary endpoint: Dose-limiting toxicity during induction. Started Jul 2016; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12616000445471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000445471.